๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for EGFR

Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR NCT06868771NA1 site๐Ÿ“ Roma Societa Italiana di Dermatologia Medica, Chirurgica, Estetiโ€ฆ ยท Tests: topical treatment with the pre- and postbiotic study preparation and niacinamide 4% and one with the 10% urea-based preโ€ฆ An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting NCT06749886Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: Denosumab, tislelizumab, Docetaxel A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations NCT06947811Phase 1, Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Almonertinib, Palbociclib ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) NCT06415487Phase 19 sites๐Ÿ“ San Diego๐Ÿ“ Denver๐Ÿ“ Nashville Acepodia Biotech, Inc. ยท Tests: Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: ORIENT-31 regimen, SBRT EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT A Phase I Study of CFT8919 in Patients With Advanced NSCLC NCT06641609Phase 11 site๐Ÿ“ Hangzhou Betta Pharmaceuticals Co., Ltd. ยท Tests: Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8โ€ฆ Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel NCT06483555Phase 1, Phase 21 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Boston Taiho Oncology, Inc. ยท Tests: TAS6417, CYP Cocktail, Transporter Cocktail A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site๐Ÿ“ Jerusalem Hadassah Medical Organization ยท Tests: Stereotactic surgery A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites๐Ÿ“ Newport Beach๐Ÿ“ San Diego๐Ÿ“ San Francisco Bayer ยท Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors NCT06598800Phase 134 sites๐Ÿ“ Hackensack๐Ÿ“ Houston๐Ÿ“ Fairfax BeOne Medicines ยท Tests: Drug: BG-T187, Other Therapeutic Agents GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFฮฒ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers NCT03198052Phase 12 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Second Affiliated Hospital of Guangzhou Medical University ยท Tests: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFฮฒ, HER2, Lewis-Y, AXL, or EGFR Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rฮฑ2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas NCT07544992Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDGโ€ฆ ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC NCT06816992Phase 14 sites๐Ÿ“ New York๐Ÿ“ Fairfax๐Ÿ“ Melbourne ORIC Pharmaceuticals ยท Tests: ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib NCT06668103Phase 25 sites๐Ÿ“ Hefei๐Ÿ“ Harbin๐Ÿ“ Wuhan Abbisko Therapeutics Co, Ltd ยท Tests: ABSK043 in combination with Firmonertinib Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Capecitabine EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC NCT07617805Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy NCT07109531Phase 31 site๐Ÿ“ Shanghai Jiangsu Aosaikang Pharmaceutical Co., Ltd. ยท Tests: ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy NCT07892573NA1 site๐Ÿ“ Ningbo Ningbo Medical Center Lihuili Hospital ยท Tests: Becotatug Vedotin, Anti-PD-1 antibody, S-1 Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site๐Ÿ“ Nanchang Second Affiliated Hospital of Nanchang University ยท Tests: Vebreltinib, Furmonertinib 80mg A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations NCT06514027Phase 21 site๐Ÿ“ Guangzhou BeBetter Med Inc ยท Tests: BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection, Cisplatin Injection Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC NCT07224841n/a1 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation) HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 NCT06369831Phase 27 sites๐Ÿ“ Innsbruck๐Ÿ“ Brussels๐Ÿ“ Brussels Abscint NV/SA ยท Tests: 68Ga-NOTA-ABSCINT-HER2 PET/CT To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT04853342Phase 31 site๐Ÿ“ Suzhou Allist Pharmaceuticals, Inc. ยท Tests: Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558Phase 1, Phase 21 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: LMV-12(HE003) Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy NCT05985954Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cetuximab, Ulixertinib, Encorafenib MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC NCT07235566Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: MRG003 in combination with pucotenlimab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy